Lidocaine

Search ⌘K Suggest Edit Sign in Medical uses Adverse effects Pharmacology Chemistry History Veterinary uses Society and culture References Fact-checked by Grok 6 months ago Lidocaine Lidocaine, also known as lignocaine, is a synthetic amide-type local anesthetic and class Ib antiarrhythmic agent that blocks voltage-gated sodium channels in neuronal and cardiac cell membranes, thereby inhibiting nerve impulse conduction to provide pain relief and suppress abnormal heart rhythms.[1][2] First synthesized in 1943–1946 by Swedish chemists Nils Löfgren and Bengt Lundquist, it was introduced clinically in 1948 and rapidly gained global adoption due to its favorable safety profile compared to earlier anesthetics like cocaine.[1] As a versatile medication, lidocaine is primarily used for local and regional anesthesia in procedures such as dental work, minor surgery, nerve blocks, and epidural administration, often combined with epinephrine to prolong its effects and reduce systemic absorption.[1][3] It is also employed intravenously to treat acute ventricular tachyarrhythmias, particularly those following myocardial infarction or cardiac surgery, and serves as an adjuvant for managing acute and chronic pain conditions, including neuropathic pain and postherpetic neuralgia via transdermal patches.[1][2] Off-label applications include treatment of interstitial cystitis and as a topical agent for anorectal discomfort (commonly applied as lidocaine (lignocaine) jelly 5-20 minutes before defecation to relieve pain during bowel movements in conditions such as anal fissures or hemorrhoids, with the anesthetic effect typically beginning within 5 minutes of application) or skin numbing.[1][4][5] Lidocaine is included on the World Health Organization's List of Essential Medicines for its critical role in anesthesia and emergency cardiac care.[2] Over-the-counter lidocaine creams (typically 4-5% strength) are available for temporary relief of minor muscle/joint pain, burns, itch, or discomfort, but they are not indicated or approved for phantom limb pain or stump pain. Evidence for topical lidocaine in these conditions is limited and mixed; some studies suggest possible benefit for stump (residual limb) pain but not phantom limb pain, and most involve prescription formulations like 5% patches (approved only for postherpetic neuralgia).[6][7][8] Standard treatments for phantom limb pain include NSAIDs/acetaminophen (OTC), gabapentin, antidepressants, mirror therapy, and others; consult a healthcare provider for appropriate management. Lidocaine's mechanism involves rapid binding to sodium channels in their inactivated state, preventing depolarization and propagation of action potentials in nerves, which results in reversible loss of sensation without causing unconsciousness.[1][2] In the heart, it shortens the action potential duration and effective refractory period, making it effective against ventricular arrhythmias but less so for atrial ones.[1] It exhibits additional properties as an N-methyl-D-aspartate (NMDA) receptor antagonist, contributing to its analgesic effects in certain pain syndromes.[1] Pharmacologically, lidocaine has a rapid onset of action—within 1 minute for intravenous administration and 15 minutes for intramuscular—and a duration of 10–20 minutes IV or 60–90 minutes IM, with a half-life of 1.5–2 hours in healthy adults, primarily metabolized in the liver by cytochrome P450 enzymes (CYP1A2 and CYP3A4) and excreted mainly via the kidneys.[1][2] It is approximately 65% protein-bound in plasma and available in various formulations, including injections (0.5%–4%), topical gels or creams (2%–5%), and patches, with the chemical formula C14H22N2O and a molecular weight of 234.34 g/mol.[2][3] Adverse effects are dose-dependent, with toxicity occurring at plasma levels above 5 μg/mL, manifesting as central nervous system symptoms like tinnitus, dizziness, seizures, or coma, and cardiovascular depression at higher concentrations.[1] Rare risks include methemoglobinemia, hypersensitivity reactions, and anaphylaxis, necessitating careful monitoring in patients with hepatic impairment, heart failure, or those receiving CYP inhibitors.[1][3] Medical uses Local anesthesia Lidocaine serves as a primary local anesthetic agent, providing reversible blockade of nerve conduction to numb targeted areas for minor surgical procedures, dental work, and diagnostic interventions. It is commonly employed in infiltration anesthesia, where it is injected directly into tissues to anesthetize small areas, such as for skin biopsies or suturing wounds. In topical applications, lidocaine is used to numb mucous membranes and skin surfaces, facilitating procedures like endoscopy, laryngoscopy, or dental extractions without invasive injections.[1][9] Historically, lidocaine marked a significant advancement as the first synthetic amide local anesthetic, developed in 1943 by Swedish chemist Nils Löfgren and introduced clinically in 1948, effectively replacing cocaine—the previously dominant ester-based anesthetic notorious for its addictive potential and systemic toxicity. This shift addressed the limitations of early agents like cocaine, which had been used topically since the late 19th century but posed risks of cardiovascular stimulation and dependence.[10][1] For regional anesthesia, lidocaine enables nerve blocks, epidural, and spinal techniques to achieve broader numbness, such as in labor pain management or orthopedic surgeries, by targeting specific nerve roots or the spinal canal. Examples include ultrasound-guided interscalene blocks for shoulder procedures or caudal blocks for lower body anesthesia. Dosage varies by route and specific block: 1% to 2% solutions are standard for infiltration and nerve blocks. For 1% lidocaine (10 mg/mL), common volumes from pharmaceutical guidelines include 10-20 mL (100-200 mg) for peripheral nerve or plexus blocks, 3-5 mL (30-50 mg) for intercostal or paravertebral blocks, 5-10 mL (50-100 mg) for vagosympathetic blocks, and 25-30 mL (250-300 mg) for epidural analgesia. The maximum single dose is typically 300-400 mg (30-40 mL of 1%) or 4.5 mg/kg without epinephrine (or 7 mg/kg with epinephrine). Doses must always be calculated individually based on patient weight, clinical guidelines, and other factors, with careful technique including aspiration tests to avoid intravascular injection and prevent systemic toxicity.[11][1] Topical formulations include 4% to 5% gels or ointments for mucosal or skin application, limited to 9 mg/kg to avoid systemic absorption.[1][9] Compared to ester anesthetics like procaine, lidocaine offers advantages including a longer duration of action—typically 1 to 2 hours for infiltration versus under 1 hour for procaine—and lower allergenicity, as amides do not produce para-aminobenzoic acid metabolites that trigger hypersensitivity in ester-sensitive patients. Lidocaine's intermediate onset of action, around 2 to 5 minutes for injections, further enhances its versatility over slower-acting esters.[12][9] Cardiac arrhythmias Lidocaine is indicated for the treatment of life-threatening ventricular arrhythmias, including pulseless ventricular tachycardia (VT) and ventricular fibrillation (VF), particularly in the setting of cardiac arrest refractory to defibrillation.[13] It has also been used historically to suppress ventricular arrhythmias following acute myocardial infarction (MI), such as premature ventricular contractions and VT, to prevent progression to VF.[14] Through its blockade of sodium channels in cardiac tissue, lidocaine slows conduction and prolongs the refractory period in ischemic or depolarized myocardium, thereby stabilizing rhythm. In emergency cardiac care, lidocaine is administered intravenously as a bolus dose of 1 to 1.5 mg/kg, followed by additional boluses of 0.5 to 0.75 mg/kg if needed, up to a total of 3 mg/kg, and then by continuous infusion at 1 to 4 mg/min to maintain therapeutic effect.[15] These protocols align with Advanced Cardiovascular Life Support (ACLS) recommendations, where lidocaine serves as an alternative antiarrhythmic to amiodarone for stable or pulseless VT/VF unresponsive to initial defibrillation attempts.[13] The 2025 American Heart Association (AHA) ACLS guidelines emphasize its role in out-of-hospital and in-hospital cardiac arrest scenarios, though evidence from randomized trials shows no significant survival benefit over placebo in terms of return of spontaneous circulation or neurologic outcomes.[13][16] Effective use requires continuous electrocardiogram (ECG) monitoring to assess rhythm response and detect any proarrhythmic effects, alongside periodic measurement of plasma lidocaine levels to ensure concentrations remain within the therapeutic range of 1.5 to 5 mcg/mL and avoid toxicity.[17] Overdose can paradoxically exacerbate arrhythmias due to excessive sodium channel blockade. The routine prophylactic administration of lidocaine in acute MI has declined significantly since the 1980s, following meta-analyses demonstrating no reduction in mortality and an increased risk of asystole and adverse events, leading to its removal from standard post-MI protocols.[18][19] Currently, it is reserved for specific refractory cases where amiodarone is ineffective or unavailable, reflecting a shift toward more selective application in evidence-based emergency care.[13][19] Other medical applications Lidocaine is employed in intravenous infusions for managing various forms of chronic pain, including neuropathic, musculoskeletal, and burn-related conditions, where it has demonstrated efficacy in reducing pain intensity and opioid requirements. A 2024 systematic review found that intravenous lidocaine infusions provided superior relief for neuropathic pain compared to placebo in the immediate post-infusion period, with effects persisting for weeks in some cases. Recent studies from 2025 further support its role in burn pain management, showing significant reductions in opioid consumption among patients with burn injuries when lidocaine is administered intravenously. These infusions typically involve doses of 1-5 mg/kg over 30-60 minutes, offering a non-opioid alternative for refractory pain. Topical 5% lidocaine patches are approved and widely used for acute localized neuropathic pain, particularly in post-herpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN). Clinical trials have established their efficacy, with one randomized controlled trial demonstrating comparable or superior pain reduction to pregabalin in PHN patients, alongside improvements in quality of life and sleep. In DPN, application of up to four patches daily for 12-18 hours significantly alleviated pain scores and enhanced daily functioning, with a favorable tolerability profile and minimal systemic absorption. These patches target peripheral sodium channels to interrupt pain signaling without the side effects of systemic therapies. While prescription 5% lidocaine patches are approved for specific neuropathic indications, over-the-counter lidocaine creams (typically 4-5% strength) are available for the temporary relief of minor muscle and joint pain, burns, itching, or skin discomfort. These OTC products are not indicated or approved for phantom limb pain or stump (residual limb) pain. Evidence for topical lidocaine in these conditions is limited and mixed; some studies suggest possible benefit for stump pain relief but little to no effect on phantom limb pain itself, with most research involving prescription formulations such as 5% patches (approved only for postherpetic neuralgia). Standard treatments for phantom limb pain include over-the-counter NSAIDs or acetaminophen, gabapentin, antidepressants, mirror therapy, and other modalities. Patients should consult a healthcare provider for appropriate management.[8][20][21][22] Nebulized lidocaine has emerged as a safe option for suppressing intractable cough in palliative and hospice care settings, particularly for cancer patients. A 2025 systematic review of 58 studies reported rapid onset of cough relief (within 15 minutes) in approximately 70% of cases using 1-4% concentrations, with effects lasting 2-4 hours and low incidence of mild side effects like dysgeusia. This non-invasive delivery minimizes systemic exposure, making it suitable for end-of-life symptom management where traditional antitussives fail. In perioperative settings for cancer surgery, intravenous lidocaine infusions exhibit anti-inflammatory effects that may inhibit tumor metastasis by reducing pro-inflammatory cytokines and neutrophil extracellular traps. A 2024 narrative review highlighted lidocaine's role in modulating the surgical stress response, potentially decreasing tumor cell migration and recurrence risk through suppression of epithelial-mesenchymal transition signaling when combined with general anesthetics. Dosing typically involves a bolus of 1-1.5 mg/kg followed by infusion at 1-3 mg/kg/h during surgery, with ongoing investigations into long-term oncologic outcomes. Lidocaine is combined with nifedipine in topical ointments (0.3% nifedipine and 1.5% lidocaine) for conservative treatment of acute thrombosed external hemorrhoids, providing both analgesic and vasodilatory effects. Randomized trials have shown resolution rates of up to 92% after two weeks of twice-daily application, with significant pain relief and healing superior to controls, attributed to lidocaine's local anesthesia complementing nifedipine's sphincter relaxation. Lidocaine jelly (typically 2%) is also commonly applied topically to provide pain relief during bowel movements in patients with anal fissures or hemorrhoids. It is often applied 5-20 minutes before defecation, with the anesthetic effect typically beginning within 5 minutes of application.[1][23][24] Similarly, in endoscopic procedures such as submucosal dissection (ESD), intravenous or submucosal lidocaine reduces analgesic and sedative needs while controlling intraoperative pain; one study reported decreased propofol requirements and post-procedural discomfort without increased complications. Investigational applications include adjunctive use in procedural sedation, where intravenous lidocaine reduces propofol doses by 30-50% during endoscopy, improving sedation quality and recovery times in elderly patients. For retinopathy treatments, particularly intravitreal injections in diabetic retinopathy, topical or subconjunctival 2% lidocaine provides effective pain control, with studies confirming mild procedural discomfort and high patient tolerance across various administration forms. Adverse effects Common side effects Lidocaine, when used topically or via injection for local anesthesia, commonly causes mild local reactions at the application or administration site, including skin irritation, erythema, and a burning or stinging sensation.[25] Allergic contact dermatitis represents a notable local adverse effect, with an overall incidence of 2.4% among users of local anesthetics, of which approximately 32% of cases are attributed to lidocaine.[26] These local effects are typically transient and resolve without intervention upon discontinuation of the drug. Systemic side effects from lidocaine absorption during therapeutic use often manifest as mild central nervous system (CNS) disturbances, such as lightheadedness, dizziness, drowsiness, tinnitus, and a metallic taste in the mouth.[1][27] These symptoms can occur at the upper end of therapeutic plasma concentrations (1.5–5 mcg/mL for antiarrhythmic use), with toxicity symptoms more prominently above 5 mcg/mL, and clinical reports indicating mild CNS effects like nervousness or confusion in less than 10% of patients receiving intravenous infusions for cardiac arrhythmias.[1] At higher but still non-toxic plasma levels, tremors or mild confusion may emerge, related to lidocaine's blockade of sodium channels in neuronal tissues.[28] Cardiovascular effects at standard therapeutic doses are uncommon but can include bradycardia or hypotension, particularly with intravenous administration or significant systemic absorption from large topical applications.[29] These are dose-related and typically mild, affecting a small proportion of patients (incidence not precisely quantified in general use but reported in up to 5% of intravenous cases in clinical monitoring data).[1] Monitoring plasma levels helps prevent escalation to more severe reactions.[1] Drug interactions Lidocaine, primarily metabolized in the liver by cytochrome P450 enzymes such as CYP1A2 and CYP3A4, is susceptible to pharmacokinetic interactions with inhibitors of these pathways, which can elevate plasma concentrations and heighten toxicity risks including central nervous system (CNS) effects and cardiac disturbances.[30] Cimetidine, a non-specific CYP inhibitor, significantly reduces lidocaine clearance, leading to increased serum levels and potential toxicity in up to 93% of coadministered patients, necessitating close monitoring or dose reduction.[31] Certain beta-blockers, such as propranolol, can potentiate lidocaine's cardiac effects by further inhibiting CYP3A4-mediated metabolism, raising the risk of bradycardia or hypotension, particularly in patients with underlying heart conditions.[32][33] Concurrent use with antiarrhythmic agents like amiodarone can exacerbate these risks through CYP3A4 inhibition, increasing lidocaine's area under the curve by approximately 15% and promoting additive bradycardia or conduction abnormalities.[34][30] Lidocaine's CNS depressant properties at higher doses can be amplified when combined with opioids such as morphine or sedatives, resulting in enhanced sedation, dizziness, and respiratory depression due to synergistic effects on neural inhibition.[35][28] Erythromycin, a strong CYP3A4 inhibitor, prolongs lidocaine's elimination half-life from about 2.5 hours to 2.9 hours, potentially leading to accumulation and prolonged effects during intravenous administration.[36] Fluoxetine, through moderate inhibition of CYP enzymes, can elevate lidocaine serum concentrations, intensifying adverse effects like drowsiness and confusion.[37][38] In polypharmacy scenarios, especially among elderly patients with diminished hepatic function, these interactions underscore the need for dose adjustments, such as reducing lidocaine loading doses by 25-50% or extending infusion intervals, alongside therapeutic plasma level monitoring to mitigate toxicity.[39][40] Contraindications Lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type, as severe allergic reactions, including anaphylaxis, may occur.[41] Absolute contraindications also include severe degrees of sinoatrial, atrioventricular, or intraventricular heart block, Stokes-Adams syndrome, and Wolff-Parkinson-White syndrome, particularly in the absence of an artificial pacemaker, due to the risk of exacerbating conduction disturbances and leading to cardiac arrest.[42] Relative contraindications warrant caution and dose adjustment. In patients with hepatic disease, lidocaine metabolism is impaired, potentially prolonging its half-life by twofold or more and increasing the risk of toxicity; lower doses and close monitoring are recommended.[42] Similarly, individuals with heart failure or impaired cardiovascular function require careful use, as reduced clearance and compensatory mechanisms may heighten the potential for hypotension, bradycardia, or arrhythmias.[41] Lidocaine should be avoided in patients with acute porphyria, as it is porphyrinogenic and may precipitate acute attacks.[43] Severe bradycardia is a relative contraindication, given lidocaine's potential to further depress sinus node function and induce sinus arrest, especially in vulnerable patients.[44] During pregnancy, lidocaine is classified as FDA Pregnancy Category B, indicating no evidence of fetal risk in animal studies but limited human data; it readily crosses the placenta, so administration should occur only if the potential benefit justifies the risk to the fetus.[42] Overdose and toxicity Local anesthetic systemic toxicity (LAST) represents a potentially life-threatening complication of lidocaine overdose, resulting from excessive plasma concentrations that primarily affect the central nervous system (CNS) and cardiovascular system. The therapeutic plasma range for lidocaine is 1.5–5 μg/mL, providing effective analgesia or antiarrhythmic effects without significant adverse outcomes.[1] Plasma levels exceeding this threshold can lead to toxicity, with CNS excitation manifesting at concentrations >5 μg/mL, including symptoms such as agitation, tinnitus, perioral numbness, muscle twitching, and seizures, while levels >8 μg/mL may precipitate severe cardiovascular collapse, including hypotension, arrhythmias, and cardiac arrest.[45][46] Risk factors for lidocaine overdose and LAST include rapid intravenous injection, unintended vascular uptake during regional blocks, and administration exceeding recommended doses, which can elevate plasma levels abruptly. In non-anesthesia settings, such as subcutaneous injections by non-anesthesiologists, overdose is a predominant cause, accounting for approximately 68% of LAST cases, with lidocaine implicated in 75% of those involving local anesthetics, according to 2025 data highlighting increased incidents in diverse medical practices. As of 2025, analyses indicate a significant increase in lidocaine-related LAST, with it accounting for approximately 75% of overdose cases and a higher proportion of fatalities (average 49 deaths/year vs. 13 for other anesthetics), often in non-anesthesia procedures.[45][47] Drug interactions, such as those with CYP3A4 inhibitors, may contribute to elevated plasma levels and exacerbate toxicity risk.[45][47] Management of lidocaine-induced LAST prioritizes immediate supportive care, including airway management with oxygenation and ventilation to address respiratory depression or apnea. Seizures should be controlled with benzodiazepines, such as midazolam or lorazepam, while avoiding propofol if cardiovascular instability is present. Lipid emulsion therapy, using 20% Intralipid as a 1.5 mL/kg intravenous bolus followed by an infusion of 0.25 mL/kg/min, is the cornerstone for reversing toxicity by sequestering the lipophilic drug from tissues. Vasopressin should be avoided due to its potential to worsen cardiac toxicity; instead, amiodarone is preferred for ventricular arrhythmias per advanced cardiac life support protocols.[48][49][50] Recent guidelines, such as the 2020 ASRA checklist for LAST treatment and 2025 reviews on local anesthetic systemic toxicity, emphasize prevention through vigilant dosing limits (e.g., ≤4.5 mg/kg without epinephrine), use of ultrasound guidance for blocks to minimize vascular injection, and incremental administration with frequent aspiration to detect intravascular placement. These measures, informed by ongoing surveillance of LAST incidents, have reduced overall morbidity but underscore the need for heightened awareness in high-risk scenarios like outpatient procedures.[51][52] Postarthroscopic glenohumeral chondrolysis Postarthroscopic glenohumeral chondrolysis (PAGCL) is a rare yet devastating complication involving the rapid and progressive degeneration of articular cartilage in the shoulder joint following arthroscopic procedures, typically manifesting as severe pain, joint stiffness, restricted range of motion, and eventual osteoarthritis-like changes that may necessitate total shoulder arthroplasty.[41] Symptoms often emerge within 1 to 6 months postoperatively, with no established effective treatment beyond supportive care and surgical intervention in advanced cases.[53] This condition has been strongly linked to the postoperative use of continuous intra-articular infusions of local anesthetics, particularly through indwelling pain pumps delivering concentrations such as 0.5% or 2% lidocaine for extended periods (often 48 to 72 hours or longer).[53][41] While bupivacaine has been implicated in the majority of reported cases, lidocaine infusions have also been associated with PAGCL in clinical reports, with laboratory evidence demonstrating its dose- and time-dependent toxicity to chondrocytes.[53] In a systematic review of 167 chondrolysis cases following shoulder arthroscopy, 97.7% involved such intra-articular pain pump infusions, highlighting the elevated risk compared to procedures without them (incidence of 40.6% versus 0%).[53] In December 2009, the U.S. Food and Drug Administration (FDA) issued a public health notification based on approximately 35 adverse event reports of chondrolysis associated with continuous intra-articular local anesthetic infusions, including lidocaine, after arthroscopic and other surgical procedures; this led to updated warnings in lidocaine product labeling advising against such use.[41][54] Case reports and studies documenting PAGCL have persisted into the 2020s, though the overall incidence remains low due to increased awareness and practice changes, with isolated instances reported as recently as 2024.[55][56] The proposed mechanisms of lidocaine-induced chondrotoxicity involve direct cellular damage to chondrocytes, including apoptosis, necrosis, mitochondrial dysfunction, and disruption of the extracellular matrix, which are amplified by high concentrations (e.g., ≥1%) and prolonged exposure exceeding 24 hours in vitro.[57][53] Additives like epinephrine, commonly included in infusion solutions to prolong anesthetic effect, may further contribute by altering local pH or enhancing toxicity, though some studies suggest a potential protective role under short exposures.[58][59] Prevention strategies emphasize avoiding continuous intra-articular lidocaine infusions altogether, as they are not FDA-approved for this route and carry substantial risk; instead, single-injection peripheral nerve blocks or systemic analgesia are preferred for postoperative shoulder pain control to minimize direct cartilage exposure.[41][53] Even short-term intra-articular lidocaine use should be limited to low doses and volumes, with ongoing monitoring for early signs of joint deterioration.[57] Pharmacology Mechanism of action Lidocaine primarily exerts its pharmacological effects by binding to voltage-gated sodium channels (NaV) in neuronal and cardiac cell membranes, inhibiting the influx of sodium ions (Na+) through the channel pore.[60] This blockade stabilizes the membrane in a depolarized state, preventing the rapid depolarization phase of the action potential and thereby inhibiting the generation and propagation of nerve impulses.[28] The interaction occurs in a 1:1 stoichiometry, with lidocaine accessing its binding site within the channel's inner vestibule, particularly in the open conformation.[61] The drug demonstrates state-dependent binding affinity to NaV channels, which cycle through resting (closed), open (activated), and inactivated states during membrane depolarization.[62] Lidocaine exhibits low affinity for the resting state but binds with higher affinity to the open and inactivated states, a property known as use-dependence.[63] This preferential binding to activated or recovering channels enhances its efficacy in rapidly firing tissues, such as ischemic myocardium, where frequent depolarizations increase channel availability in non-resting states.[64] In addition to its primary sodium channel blockade, lidocaine weakly inhibits certain voltage-gated potassium channels, including ATP-sensitive KATP channels and two-pore domain channels like TREK-1, which may modulate membrane repolarization and excitability at higher concentrations.[65][66] Lidocaine also displays anti-inflammatory effects by modulating neutrophil activity, such as inhibiting priming, reducing extracellular trap formation, and suppressing the respiratory burst in activated neutrophils.[67][68] As an amide-type local anesthetic, lidocaine's chemical structure features an amide linkage between its aromatic and amine components, distinguishing it from ester-type agents and enabling its metabolism primarily by hepatic cytochrome P450 enzymes rather than plasma esterases.[69] This structural difference contributes to its pharmacokinetic profile but does not directly alter its binding mechanism at sodium channels.[70] Pharmacokinetics Lidocaine is rapidly absorbed following intravenous administration, achieving peak plasma concentrations almost immediately, while absorption from other routes is variable depending on the site of application, formulation, and dosage. For instance, topical application to mucous membranes exhibits variable bioavailability, influenced by the drug's pKa of 7.9, which results in a higher proportion of the ionized form at physiological pH, limiting passive diffusion across lipid membranes.[28][1] Intramuscular or subcutaneous injections lead to slower absorption, with peak levels occurring within 10-30 minutes, and factors such as vasoconstrictors like epinephrine can prolong this by reducing vascular uptake.[1] The drug distributes widely throughout the body, with a volume of distribution of about 1.1 L/kg, reflecting its moderate lipophilicity and ability to penetrate tissues. Approximately 60-70% of lidocaine is bound to plasma proteins, primarily alpha-1-acid glycoprotein and albumin, which can vary with disease states like inflammation. It readily crosses the blood-brain barrier and the placenta via passive diffusion, potentially leading to fetal exposure during maternal administration.[1][71][28] Metabolism occurs primarily in the liver through cytochrome P450 enzymes, including CYP3A4 and CYP1A2, producing active metabolites such as monoethylglycinexylidide (MEGX), which retains about 80% of lidocaine's activity, and glycinexylidide (GX), a less potent but longer-lasting metabolite. The elimination half-life of lidocaine is typically 1.5-2 hours in healthy adults, though this can extend in conditions like hepatic impairment due to reduced metabolic capacity.[1] Elimination is predominantly renal, with over 90% of the dose excreted as metabolites in urine, and less than 10% as unchanged drug. Clearance is flow-dependent, approximating hepatic blood flow, and is prolonged in liver disease or heart failure. Recent population pharmacokinetic models for intravenous lidocaine in adults highlight covariates such as age and body weight, enabling tailored dosing to minimize variability and toxicity risk.[1][72] Chemistry Synthesis Lidocaine is synthesized via a classic two-step process originally developed by Swedish chemist Nils Löfgren in 1943.[73] In the first step, 2,6-dimethylaniline undergoes acylation with chloroacetyl chloride to form the intermediate 2-chloro-N-(2,6-dimethylphenyl)acetamide. This reaction is typically conducted in a solvent such as dichloromethane or acetic acid at 0°C to room temperature, often in the presence of a base like sodium acetate to neutralize the generated HCl and prevent over-acylation.[74] The second step involves an SN2 nucleophilic displacement of the chloride by diethylamine, yielding lidocaine as the free base. This substitution is performed in a solvent like ethanol or without solvent, at room temperature or under reflux, sometimes with added base such as potassium carbonate to facilitate the reaction.[74] The overall yield of this two-step process is typically 70-80%, depending on scale and conditions.[74] Purification involves isolating the intermediate by filtration after the first step, followed by conversion of the final product to its hydrochloride salt through treatment with aqueous HCl or HCl gas in diethyl ether, yielding a precipitate that is filtered, washed, and recrystallized from solvents like ethanol or acetone to achieve pharmaceutical purity.[75] On an industrial scale, the synthesis follows the same two-step route but with optimizations for efficiency, safety, and impurity control to meet regulatory standards for active pharmaceutical ingredients. Processes employ controlled reactors for the acylation step at low temperatures to minimize side products, followed by high-purity diethylamine displacement under inert conditions, achieving yields above 85% with rigorous distillation and crystallization for the hydrochloride form.[76] Recent greener variants have emerged to reduce solvent use, energy consumption, and hazardous reagents. Microwave-assisted methods accelerate the substitution step under solventless or minimal-solvent conditions, improving yields to 46-71% for individual steps while eliminating volatile organic solvents like toluene.[77] Additionally, a 2022 room-temperature multicomponent Ugi three-component reaction combines 2,6-dimethylaniline, chloroacetic acid, and diethylformamide diethyl acetal (as an isocyanide equivalent) in methanol, offering excellent atom economy and simplified workup with yields comparable to classical methods, suitable for educational and scalable applications.[78] Structure and properties Lidocaine, chemically known as 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide, has the molecular formula C14H22N2O and a molecular weight of 234.34 g/mol.[2] This compound features an amide linkage connecting a diethylamino-substituted acetamide group to a 2,6-dimethylphenyl ring, with the amide bond contributing to its chemical stability compared to ester-based anesthetics.[2] As a physical entity, lidocaine appears as a white to slightly yellow crystalline powder with a characteristic odor, often forming needles when crystallized from solvents like benzene or alcohol.[2] Its melting point ranges from 66°C to 69°C.[79] The base form exhibits limited solubility in water, approximately 410 mg/L at 30°C, but is very soluble in ethanol and chloroform while being insoluble in ether.[2] Lidocaine is a weak base with a pKa of approximately 7.9 for its conjugate acid, corresponding to the tertiary amine group, which influences its ionization state near physiological pH where a significant portion remains protonated.[2] Regarding stability, lidocaine is relatively resistant to hydrolysis due to its amide structure, though it can degrade under extreme conditions involving metal ions or specific pH extremes; it maintains optimal stability in aqueous solutions at pH 3–6.[80] Commercially, it is typically stored and used as the hydrochloride salt to enhance water solubility, protected from light and excessive heat at 20–25°C.[2] Conformational behavior Lidocaine exhibits conformational flexibility primarily around the amide linkage, with preferred conformations identified through spectroscopic and computational methods. Nuclear magnetic resonance (NMR) studies, combined with lanthanide-induced shifts and molecular mechanics calculations, reveal dynamic interconversion in the aliphatic chain, though the gauche form predominates around the amide bond.[81] Density functional theory (DFT) calculations at the B3LYP/6-311G** level support a non-planar cis conformation (NCCN torsional angle ≈ 0°) as the lowest energy form for the amide bond, approximately 2-6 kcal/mol more stable than the trans counterpart (NCCN ≈ 180°).[82] Infrared (IR) and Raman spectra confirm the predominance of this cis conformation at room temperature, with vibrational modes consistent with the cis form, while ^1H and ^13C NMR chemical shifts match DFT predictions (RMSD values of 0.47 ppm and 8.26 ppm, respectively).[82] This cis arrangement aligns with the crystal structure of lidocaine.[82] The rotational barrier for C-N bond rotation in the amide group is approximately 15-20 kcal/mol, characteristic of partial double-bond character due to resonance, allowing restricted but observable flexibility on appropriate timescales.[83] The ortho-methyl substituents on the phenyl ring significantly influence the amide conformation by introducing steric hindrance, resulting in a twist of about 72° between the amide plane and the aromatic ring, which stabilizes the planar amide geometry while restricting free rotation around the aryl-nitrogen bond.[84] This steric effect enhances the rigidity of the aromatic-amide moiety. NMR evidence underscores the flexibility of the aliphatic chain, with variable-temperature studies and lanthanide shifts indicating dynamic interconversion between gauche and anti forms around the amide-carbonyl bond, though the gauche predominates.[81] This conformational adaptability, particularly in the flexible diethylaminoacetamide tail, facilitates lidocaine's interaction with the sodium channel binding site by allowing the molecule to adjust its shape for optimal hydrophobic and electrostatic fit during blockade.[81] History Discovery Lidocaine was first synthesized in 1943 by Swedish chemists Nils Löfgren and Bengt Lundqvist at the University of Stockholm, as part of efforts to develop safer alternatives to cocaine and its derivatives amid wartime shortages of natural sources.[85][86] Their work built on earlier research into amide-linked compounds, aiming to create local anesthetics with improved stability and reduced toxicity compared to ester-based agents like procaine.[87] Initial pharmacological evaluation involved animal studies conducted by pharmacologist Leonard Goldberg, which demonstrated that the new compound, initially designated LL30, exhibited superior potency and safety to procaine. These tests showed LL30 provided faster onset of anesthesia and approximately four times the duration of action, while producing less tissue irritation and systemic toxicity. Bengt Lundqvist then performed the first human tests by self-administering the compound.[86] The compound's amide structure contributed to its enhanced profile, marking a significant advancement in local anesthetic design.[88] The drug was named "Xylocaine," derived from its precursor 2,6-xylidine, a dimethylaniline derivative used in the synthesis.[89] Löfgren detailed the synthesis, chemical properties, and preliminary pharmacology in his 1948 doctoral thesis, Studies on Local Anesthetics: Xylocaine, a New Synthetic Drug, published in Stockholm, which served as the foundational documentation of the discovery.[90] This work established lidocaine as the first widely successful amide local anesthetic.[91] Development and clinical introduction Lidocaine was introduced into clinical practice in Sweden in 1948 following extensive testing by anesthesiologist Torsten Gordh, who demonstrated its superior potency and safety profile compared to procaine for local and regional anesthesia, including intravenous administration for systemic effects. Gordh's trials, conducted at Karolinska Hospital, confirmed effective spinal, infiltration, and topical anesthesia with rapid onset and minimal irritation, paving the way for its adoption as a safer alternative to ester-type anesthetics.[91] The U.S. Food and Drug Administration granted approval for lidocaine's topical use in November 1948 under the trade name Xylocaine, marketed by Astra AB (now part of AstraZeneca), marking its rapid commercialization globally as the first amide-linked local anesthetic.[92] Injectable formulations for local and regional anesthesia followed soon after in 1949, with FDA approval for parenteral use in 1948, while its antiarrhythmic potential via intravenous administration was recognized in the 1950s through reports of successful arrhythmia suppression during cardiac procedures.[93] Veterinary applications emerged concurrently in the 1950s, expanding its utility beyond human medicine. Early clinical adoption faced challenges from reports of central nervous system and cardiovascular toxicity at higher doses, particularly with intravenous use, prompting refined dosing protocols and monitoring guidelines by the late 1950s to mitigate risks like seizures and hypotension.[94] By the 1960s, li